Suchergebnisse

PubPharm (7)

1

Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189) : a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

enthalten in: The lancet / Oncology | March 2020

von Garassino, M. | Gadgeel, S. | Esteban, E. | +16

2

Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study : evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer

enthalten in: European journal of cancer | January 2018

von Schneeweiss, A. | Chia, S. | Hickish, T. | +6

3

Two cycles of risk-adapted consolidation therapy in patients with acute promyelocytic leukemia : results from the SAL-AIDA2000 trial

enthalten in: Annals of hematology | 2015

von Röllig, C. | Ho, A.

4

Sequential chemotherapies for advanced gastric cancer : a retrospective analysis of 111 patients

enthalten in: Oncology | October 29, 2013

von Elsing, C. | Herrmann, C. | Hannig, C. | +3

5

Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia

enthalten in: Journal of clinical oncology | March 21, 2011

von Hehlmann, R. | Lauseker, M. | Jung-Munkwitz, S. | +17

6

Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy : a European MCL intergroup study

enthalten in: Blood | 2010

von Pott, C. | Hoster, E. | Delfau-Larue, M. | +22

CommentIn: Blood. 2010 Apr 22;115(16):3180-1. - PMID 20413661

7

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

enthalten in: Journal of clinical oncology | July 10 2010

von Miles, D. | Chan, A. | Dirix, L. | +13

1
[1]